![]() | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
|
![]() | The following Wikipedia contributor has declared a personal or professional connection to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view. |
We have a bunch of primary sources
And a bunch of links to the editors own website:
Editor appears to be trying to promote themselves. Doc James ( talk · contribs · email) 18:54, 18 May 2016 (UTC)
![]() | This edit request by an editor with a conflict of interest was declined. See comment by User:Doc James below. |
User:Jsvaidya has acknowledged his COI and asked here for me to construct an edit request for him. This is the content he wanted to add.
The TARGIT-A trial was an international multicenter prospective randomised phase 3 clinical trial designed to test whether a single dose of targeted intraoperative radiotherapy could replace the usual 3-6 week course of postoperative radiotherapy. The first results found no difference in cancer control and TARGIT also caused less radiotherapy related toxicity than whole breast radiotherapy [1]. The trial completed recruitment of 3451 patients in June 2012. The results, presented in the San Antonio Breast Cancer Conference in December 2012 2012 SABCS, Thursday 6 December, General Session 4 and later published [2], showed that that giving TARGIT at the time of lumpectomy, gives results similar to whole breast radiotherapy in terms of breast cancer control (particularly in ER PR positive cases), with fewer non-breast cancer deaths and a trend for lower overall mortality compared with conventional external beam whole breast radiotherapy. The results have been further clarified in the Red Journal [3].
The quality of life of patients who receive TARGIT is better than those who receive EBRT [4] Full text PDF. Analysis of distance travelled by breast cancer patients for taking their radiotherapy found that TARGIT IORT radiotherapy during lumpectomy for breast cancer could save millions of travel miles & tonnes of CO2, plus free up thousands of hours for women with early stage breast cancer, every year [5]. Full Text PDF. Video abstract.
A meta-analysis of randomised trials of partial breast irradiation (PBI) vs. whole breast irradiation (WBI) as part of breast conserving therapy demonstrated a reduction in non-breast-cancer and overall mortality. [6] Full text and Audio Slides
TARGIT as a tumour bed boost: In conventional EBRT, the boost is delivered at the end of a complete course of EBRT. Clinical evidence suggests that boost radiation improves treatment outcome for breast cancer. [7] With TARGIT the boost can be delivered intraoperatively without any delay and more precisely as compared to conventional EBRT. A multicenter clinical trial has demonstrated that the boost administered with IORT resulted in a lower than expected rate of local recurrence (1.73%) as compared to an EORTC study which used external boost radiation. [8] [9] [10]
As a tumour bed boost, TARGIT has been found to have a better than expected effectiveness [11] [9] [10] These results have prompted the inclusion of TARGIT boost as an option to EBRT boost in national clinical guidelines of many countries including Germany. Whether TARGIT is superior to an EBRT boost is being tested in a randomised trial IORT Boost TARGIT-B trial.
References
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
-- Jytdog ( talk) 05:50, 19 May 2016 (UTC)
Hello fellow Wikipedians,
I have just modified one external link on Targeted intra-operative radiotherapy. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at {{
Sourcecheck}}
).
An editor has reviewed this edit and fixed any errors that were found.
Cheers.— cyberbot II Talk to my owner:Online 17:35, 26 May 2016 (UTC)
![]() | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
|
![]() | The following Wikipedia contributor has declared a personal or professional connection to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view. |
We have a bunch of primary sources
And a bunch of links to the editors own website:
Editor appears to be trying to promote themselves. Doc James ( talk · contribs · email) 18:54, 18 May 2016 (UTC)
![]() | This edit request by an editor with a conflict of interest was declined. See comment by User:Doc James below. |
User:Jsvaidya has acknowledged his COI and asked here for me to construct an edit request for him. This is the content he wanted to add.
The TARGIT-A trial was an international multicenter prospective randomised phase 3 clinical trial designed to test whether a single dose of targeted intraoperative radiotherapy could replace the usual 3-6 week course of postoperative radiotherapy. The first results found no difference in cancer control and TARGIT also caused less radiotherapy related toxicity than whole breast radiotherapy [1]. The trial completed recruitment of 3451 patients in June 2012. The results, presented in the San Antonio Breast Cancer Conference in December 2012 2012 SABCS, Thursday 6 December, General Session 4 and later published [2], showed that that giving TARGIT at the time of lumpectomy, gives results similar to whole breast radiotherapy in terms of breast cancer control (particularly in ER PR positive cases), with fewer non-breast cancer deaths and a trend for lower overall mortality compared with conventional external beam whole breast radiotherapy. The results have been further clarified in the Red Journal [3].
The quality of life of patients who receive TARGIT is better than those who receive EBRT [4] Full text PDF. Analysis of distance travelled by breast cancer patients for taking their radiotherapy found that TARGIT IORT radiotherapy during lumpectomy for breast cancer could save millions of travel miles & tonnes of CO2, plus free up thousands of hours for women with early stage breast cancer, every year [5]. Full Text PDF. Video abstract.
A meta-analysis of randomised trials of partial breast irradiation (PBI) vs. whole breast irradiation (WBI) as part of breast conserving therapy demonstrated a reduction in non-breast-cancer and overall mortality. [6] Full text and Audio Slides
TARGIT as a tumour bed boost: In conventional EBRT, the boost is delivered at the end of a complete course of EBRT. Clinical evidence suggests that boost radiation improves treatment outcome for breast cancer. [7] With TARGIT the boost can be delivered intraoperatively without any delay and more precisely as compared to conventional EBRT. A multicenter clinical trial has demonstrated that the boost administered with IORT resulted in a lower than expected rate of local recurrence (1.73%) as compared to an EORTC study which used external boost radiation. [8] [9] [10]
As a tumour bed boost, TARGIT has been found to have a better than expected effectiveness [11] [9] [10] These results have prompted the inclusion of TARGIT boost as an option to EBRT boost in national clinical guidelines of many countries including Germany. Whether TARGIT is superior to an EBRT boost is being tested in a randomised trial IORT Boost TARGIT-B trial.
References
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
-- Jytdog ( talk) 05:50, 19 May 2016 (UTC)
Hello fellow Wikipedians,
I have just modified one external link on Targeted intra-operative radiotherapy. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at {{
Sourcecheck}}
).
An editor has reviewed this edit and fixed any errors that were found.
Cheers.— cyberbot II Talk to my owner:Online 17:35, 26 May 2016 (UTC)